...
首页> 外文期刊>PLoS Medicine >Advance care planning in patients with advanced cancer: A 6-country, cluster-randomised clinical trial
【24h】

Advance care planning in patients with advanced cancer: A 6-country, cluster-randomised clinical trial

机译:先进癌症患者的预先保健计划:一个6个国家,簇随机临床试验

获取原文

摘要

Background Advance care planning (ACP) supports individuals to define, discuss, and record goals and preferences for future medical treatment and care. Despite being internationally recommended, randomised clinical trials of ACP in patients with advanced cancer are scarce. Methods and findings To test the implementation of ACP in patients with advanced cancer, we conducted a cluster-randomised trial in 23 hospitals across Belgium, Denmark, Italy, Netherlands, Slovenia, and United Kingdom in 2015–2018. Patients with advanced lung (stage III/IV) or colorectal (stage IV) cancer, WHO performance status 0–3, and at least 3 months life expectancy were eligible. The ACTION Respecting Choices ACP intervention as offered to patients in the intervention arm included scripted ACP conversations between patients, family members, and certified facilitators; standardised leaflets; and standardised advance directives. Control patients received care as usual. Main outcome measures were quality of life (operationalised as European Organisation for Research and Treatment of Cancer [EORTC] emotional functioning) and symptoms. Secondary outcomes were coping, patient satisfaction, shared decision-making, patient involvement in decision-making, inclusion of advance directives (ADs) in hospital files, and use of hospital care. In all, 1,117 patients were included (442 intervention; 675 control), and 809 (72%) completed the 12-week questionnaire. Patients’ age ranged from 18 to 91 years, with a mean of 66; 39% were female. The mean number of ACP conversations per patient was 1.3. Fidelity was 86%. Sixteen percent of patients found ACP conversations distressing. Mean change in patients’ quality of life did not differ between intervention and control groups (T-score ?1.8 versus ?0.8, p = 0.59), nor did changes in symptoms, coping, patient satisfaction, and shared decision-making. Specialist palliative care (37% versus 27%, p = 0.002) and AD inclusion in hospital files (10% versus 3%, p 0.001) were more likely in the intervention group. A key limitation of the study is that recruitment rates were lower in intervention than in control hospitals. Conclusions Our results show that quality of life effects were not different between patients who had ACP conversations and those who received usual care. The increased use of specialist palliative care and AD inclusion in hospital files of intervention patients is meaningful and requires further study. Our findings suggest that alternative approaches to support patient-centred end-of-life care in this population are needed.
机译:背景技术预先保理计划(ACP)支持个人定义,讨论和记录未来的医疗和护理的目标和偏好。尽管是国际建议的,晚期癌症患者的ACP随机临床试验是稀缺的。方法和调查结果以测试晚期癌症患者ACP的实施,我们在2015 - 2018年在比利时,丹麦,意大利,荷兰,斯洛文尼亚和英国进行了23家医院进行了集群随机试验。晚期肺(III / IV)或结肠直肠(第四阶段)癌症的患者,绩效状况0-3,至少3个月的预期寿命有资格。尊重适用于干预ARM中的患者的选择ACP干预的行动包括患者,家庭成员和认证协调人之间的脚本对话;标准的传单;和标准化的预先指示。控制患者像往常一样接受护理。主要结果措施是生活质量(作为欧洲研究和治疗癌症的癌症组织的癌症[Eortc]情绪功能)和症状。二次结果是应对,患者满意度,共同决策,患者参与决策,包括在医院文件中的预先指示(广告)以及使用医院护理。总而言之,包括1,117名患者(442次干预; 675控制),809(72%)完成了12周的问卷。患者的年龄从18至91岁到达,平均值为66; 39%是女性。每个患者的ACP对话的平均数为1.3。保真度为86%。百分之十的患者发现ACP对话令人痛苦。患者的寿命质量的平均变化在干预和对照组之间没有差异(T-Score?1.8与β0.8,p = 0.59),也不是症状,应对,患者满意度和共同决策的变化。专业姑息治疗(37%对27%,P = 0.002)和在医院文件中的广告纳入(10%对3%,P <0.001)更有可能在干预组中。该研究的一个关键限制是,招聘率在干预率较低,而不是控制医院。结论我们的结果表明,拥有ACP对话的患者和接受通常护理的人之间的患者之间的寿命质量并不不同。在干预患者的医院档案中增加了专业姑息治疗和广告纳入的使用是有意义的,需要进一步研究。我们的调查结果表明,需要支持这种患者居住的患者终生终身保健的替代方法。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号